Krystal Biotech, Inc. (KRYS)
| Market Cap | 10.40B +143.4% |
| Revenue (ttm) | 440.48M +22.6% |
| Net Income | 241.46M +64.6% |
| EPS | 7.97 +62.4% |
| Shares Out | 29.60M |
| PE Ratio | 44.12 |
| Forward PE | 41.62 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 143,504 |
| Open | 356.92 |
| Previous Close | 357.46 |
| Day's Range | 348.57 - 356.92 |
| 52-Week Range | 136.73 - 382.54 |
| Beta | 0.54 |
| Analysts | Strong Buy |
| Price Target | 385.00 (+9.54%) |
| Earnings Date | Aug 3, 2026 |
About KRYS
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey... [Read more]
Financial Performance
In 2025, Krystal Biotech's revenue was $389.13 million, an increase of 33.94% compared to the previous year's $290.52 million. Earnings were $204.83 million, an increase of 129.74%.
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for KRYS stock is "Strong Buy." The 12-month stock price target is $385.0, which is an increase of 9.54% from the latest price.
News
Krystal Biotech initiated with an Outperform at RBC Capital
RBC Capital analyst Lisa Walter initiated coverage of Krystal Biotech (KRYS) with an Outperform rating and $400 price target Krystal is a gene therapy company focused on rare diseases treatable…
Krystal Biotech price target lowered to $392 from $396 at BofA
BofA analyst Alec Stranahan lowered the firm’s price target on Krystal Biotech (KRYS) to $392 from $396 and keeps a Buy rating on the shares after a “mixed” Q2 report.
Krystal Biotech price target raised to $386 from $378 at Citi
Citi analyst Yigal Nochomovitz raised the firm’s price target on Krystal Biotech (KRYS) to $386 from $378 and keeps a Buy rating on the shares.
Krystal Biotech Earnings Call Transcript: Q2 2026
Q2 2026 saw robust revenue growth, strong U.S. and international demand for VYJUVEK, and progress in clinical and regulatory milestones. Net revenue rose 24% year-over-year, with over 730 U.S. reimbursement approvals and continued global expansion.
Krystal Biotech Earnings release: Q2 2026
Krystal Biotech released its Q2 2026 earnings on August 3, 2026, summarizing the period's financial results.
Krystal Biotech Quarterly report: Q2 2026
Krystal Biotech has published its Q2 2026 quarterly earnings report on August 3, 2026.
Krystal Biotech Slides: Q2 2026
Krystal Biotech has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 3, 2026.
Krystal Biotech reports Q2 EPS $1.79, consensus $1.91
Reports Q2 revenue $119.22M, consensus $121.04M. “Our second quarter reflects the strength of the Krystal model: a global commercial product that continues to perform, a strong balance sheet, and a…
Krystal Biotech Announces Second Quarter 2026 Financial and Operating Results
$119.2 million in 2Q VYJUVEK global revenue and $965.9 million since launch Multiple clinical data readouts in 2H 2026 On track for VYJUVEK launches in Spain and Italy later this year Strong balance s...
Krystal Biotech Slides: Corporate presentation
Krystal Biotech has posted slides in relation to its latest quarterly earnings report, which was published on August 1, 2026.
Krystal Biotech to Report Second Quarter 2026 Financial Results on August 3, 2026
PITTSBURGH, July 23, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that it will report its second quarter 2026 financial results on Monday, August 3, 20...
Krystal Biotech Set to Join S&P MidCap 400; Tutor Perini and V2X to Join S&P SmallCap 600
NEW YORK, July 20, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400, S&P SmallCap 600
Krystal Biotech to replace Taylor Morrison in S&P 400 at open on 7/24
Berkshire Hathaway (BRK.B) (BRK.A) (BRK.A/BRK.B) is acquiring Taylor Morrison Home (TMHC) in a deal expected to close on or about that date, pending final closing conditions.
Tutor Perini to replace Krystal Biotech in S&P 600 at open on 7/24
17:18 EDT Tutor Perini (TPC) to replace Krystal Biotech (KRYS) in S&P 600 at open on 7/24
Krystal Biotech price target raised to $396 from $364 at BofA
BofA raised the firm’s price target on Krystal Biotech (KRYS) to $396 from $364 and keeps a Buy rating on the shares. The firm moderately lowered its 2026 estimates given…
Krystal Biotech price target raised to $474 from $399 at Jefferies
Jefferies raised the firm’s price target on Krystal Biotech (KRYS) to $474 from $399 and keeps a Buy rating on the shares. For Q2, the firm expects “another solid result…
Krystal Biotech price target raised to $403 from $306 at TD Cowen
TD Cowen raised the firm’s price target on Krystal Biotech (KRYS) to $403 from $306 and keeps a Buy rating on the shares. The firm sees major value from its…
Krystal Biotech price target raised to $361 from $310 at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis raised the firm’s price target on Krystal Biotech (KRYS) to $361 from $310 and keeps a Buy rating on the shares. The firm sees a…
Corbus Pharmaceuticals Announces the Appointment of Nishant Saxena as Chief Business Officer and Schedules a Pre-2026 ASCO CRB-701 Data Conference Call
NORWOOD, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP), a clinical-stage company focused on developing promising new therapies in oncology and obesity, t...
Krystal Biotech Slides: Corporate presentation
Krystal Biotech has posted slides in relation to its latest quarterly earnings report, which was published on May 20, 2026.
Krystal Biotech announces UK MHRA approval of Vyjuvek
Krystal Biotech (KRYS) announced that the United Kingdom Medicines and Healthcare products Regulatory Agency, or MHRA, granted marketing authorization to Vyjuvek for the treatment of wounds in patient...
Krystal Biotech Announces United Kingdom MHRA Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa
VYJUVEK approved for the treatment of DEB from birth with flexible administration options similar to those already granted in the United States, European Union, and Japan VYJUVEK is the first genetic...
Krystal Biotech Transcript: AGM 2026
The meeting covered director elections, auditor ratification, and compensation approvals, with all proposals passing. A brief Q&A followed the formal business, and final voting results will be filed with the SEC.
U.K.’s MHRA approves Krystal’s Vyjuvek for dystrophic epidermolysis bullosa
The Medicines and Healthcare products Regulatory Agency has approved Krystal Biotech’s (KRYS) beremagene geperpavec — Vyjuvek — for the treatment of wounds in patients with dystrophic epidermolysis bu...
Krystal Biotech Transcript: Bank of America Global Healthcare Conference 2026
Strong financial performance continues with high gross margins and expanding global launches, particularly in Europe and Japan. Pipeline progress includes fully enrolled ocular DEB and neurotrophic keratitis studies, and a cystic fibrosis program advancing toward pivotal trials.